<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137198</url>
  </required_header>
  <id_info>
    <org_study_id>SUFIN002</org_study_id>
    <nct_id>NCT04137198</nct_id>
  </id_info>
  <brief_title>Sufentanil Intranasal</brief_title>
  <official_title>The Effect of Intranasal Sufentanil on Acute Posttraumatic Pain. A Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the effects of intranasal sufentanil on patients presenting to the emergency
      department with acute post-traumatic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients presenting to the emergency department with post-traumatic pain of 7
      or more on the visual analog pain scale, since less than 24 hours, in the limbs, spine or
      thorax are randomized in a control arm or an interventional arm.

      The patients in the control arm will receive the institution's classical analgetic protocol
      level 1 and 3, the patients in the intervention arm are given classical level 1 medication as
      well as intranasal Sufentanil.

      Pain is then measured using the Visual Analogue Pail Scale at 15-20 minutes and at 60
      minutes. At both these time points, adverse effects and vitals are also assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in pain score</measure>
    <time_frame>15-20 minutes after first administration of Sufentanil</time_frame>
    <description>pain score is measured using an analogue visual pain reporting scale (0-10, 0 for no pain at all and 10 for worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in pain score</measure>
    <time_frame>60 minutes after first administration of Sufentanil</time_frame>
    <description>pain score is measured using an analogue visual pain reporting scale (0-10, 0 for no pain at all and 10 for worst pain imaginable)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of participants with adverse effects</measure>
    <time_frame>at 15-20 and at 60 minutes</time_frame>
    <description>subjects are questioned and examined for known adverse effects of Sufentanil</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Emergencies</condition>
  <condition>Pain, Acute</condition>
  <condition>Analgesia</condition>
  <condition>Sufentanil</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>classic analgetic protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal Sufentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses</description>
    <arm_group_label>intervention</arm_group_label>
    <other_name>Sufenta Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  posttraumatic pain + lasting for less than 24 hours + with an analog visual pain scale
             of 7/10 or more

        Exclusion Criteria:

          -  pregnant

          -  &lt;18 years

          -  prisoners

          -  lesions of head, face or abdomen

          -  no consent given or possible

          -  pain not scorable

          -  known drug abuse or substitution therapy

          -  chronic level 3 pain medication

          -  intake of level 3 &lt; 8 hours

          -  intoxicated patient

          -  allergy or intolerance to opiates

          -  renal or hepatic insufficiency

          -  &lt; 50kg body weight

          -  hemodynamic instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernard Kreps, MD</last_name>
    <phone>+3225353495</phone>
    <email>bernard_kreps@stpierre-bru.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Malinverni, MD</last_name>
    <email>stefano_malinverni@stpierre-bru.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint Pierre</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Malinverni, MD</last_name>
      <phone>+3225354051</phone>
      <email>stefano_malinverni@stpierre-bru.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emergency</keyword>
  <keyword>pain</keyword>
  <keyword>analgesia</keyword>
  <keyword>intranasal</keyword>
  <keyword>sufentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication all IPD will be made available through researchgate.com profile of backup investigator</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After publication</ipd_time_frame>
    <ipd_access_criteria>access will be granted to any researcher requesting access through Researchgate.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

